Background {#Sec1}
==========

Glucose-6-phosphate dehydrogenase (G6PD) is the first enzyme of the pentose phosphate pathway \[[@CR1]\] and the sole source of reduced nicotinamide adenine dinucleotide phosphate (NAPDH) required by the red blood cells to withstand oxidative stress \[[@CR2]\]. It is encoded by a highly polymorphic gene located on the X-chromosome. Over 400 G6PD single nucleotides polymorphism (SNPs) have been identified until 2012 with 186 SNPs being associated with the loss of G6PD activity and stability. The SNPs cause G6PD deficiency which clinically manifests as neonatal jaundice, acute haemolytic anaemia and chronic haemolytic anaemia \[[@CR3]\]. However, most people carrying this genetic defect are asymptomatic. Qualitative and enzyme activity tests are currently used to phenotypically classify G6PD deficiency at the point-of-care. Since G6PD deficiency is X-linked, males are classified as either G6PD normal or deficient whereas females are classified into three G6PD phenotypes, normal, intermediate and deficient \[[@CR4]\].

The geographical distribution of the various G6PD variants, as defined by the G6PD SNP (s) present, varies extensively. The most prevalent variants include G6PD B (normal), G6PD A+ (moderately deficient) and G6PD A− (severely deficient). Of this, G6PD B, the wild-type variant, is the most common variant globally \[[@CR5]\]. G6PD A+ and A− are predominantly found in people of African origin \[[@CR6], [@CR7]\]. G6PD A+ is a non-deficient variant arising from 376A\>G (rs1050829) point mutation whereas G6PD A−, the deficient variant, arises from two G6PD point mutations, namely 376A\>G and 202G\>A (rs1050828) \[[@CR8]\]. It is estimated that over 400 million people are G6PD deficient globally; making G6PD deficiency the most common human enzymopathy \[[@CR9]\].

The prevalence of G6PD deficiency is highly heterogeneous with the prevalence in the tropics ranging from for 3% to 35% \[[@CR4]\]. Globally, the highest prevalence of G6PD deficiency occurs in Sub-Saharan Africa where malaria is also prevalent \[[@CR3]\]. Due to this overlap, it has been suggested that G6PD deficiency may have arisen from natural selection by malaria. This hypothesis is supported by studies demonstrating a negative association between G6PD A− variant and severe malaria, particularly in hemizygote deficient males and homozygote deficient females \[[@CR10], [@CR11]\]. However, a recent systematic review and meta-analysis of published data from East and West Africa revealed the absence of this association \[[@CR12]\]. This study also demonstrated that G6PD deficiency may be protective against *Plasmodium falciparum* uncomplicated malaria in Africa \[[@CR12]\].

Even though G6PD deficiency is largely asymptomatic, acute haemolytic anaemia can be triggered among G6PD deficient individuals by an infection, ingestion of fava beans or certain drugs \[[@CR3], [@CR13]\]. One of the drugs known to induce acute haemolytic anaemia is primaquine \[[@CR3], [@CR14]\]. Primaquine (PQ) is an 8-aminoquinoline anti-malarial drug recommended for preventing *Plasmodium vivax* and *Plasmodium ovale* relapse provided the G6PD status is known with exception of pregnant women, children \< 6 months years and women breastfeeding children below 6 years old \[[@CR15]\].

In the context of falciparum malaria control, a single dose of PQ in combination with artemisinin-based combination therapy (ACT) is recommended for reducing *P. falciparum* transmission to the vectors \[[@CR13], [@CR15]\]. High efficacy of PQ against *P. falciparum* gametocytes offers an attractive strategy for reducing malaria transmission in the Republic of Congo and other malaria-endemic areas \[[@CR16], [@CR17]\]. However, the existing paucity of data on the prevalence of G6PD deficiency impedes the PQ administration in the Republic of Congo. This study aimed to bridge this knowledge gap by investigating the prevalence of G6PD deficiency genotypes in Brazzaville, Republic of Congo. The association between G6PD deficiency with haemoglobin levels and blood cell counts was also assessed.

Methods {#Sec2}
=======

Study site and sample collection {#Sec3}
--------------------------------

This study was conducted in Brazzaville, the capital of the Republic of Congo. Malaria transmission is perennial in this area. *Plasmodium falciparum* is the predominant cause of *Plasmodium* species infection \[[@CR18], [@CR19]\]. Two hundred and twenty-nine febrile children recruited previously during a previous study conducted at the paediatric hospital Marien NGOUABI between September 2014 and February 2015 were eligible for inclusion in the present study \[[@CR20]\]. The inclusion criteria were as follows; participants between one to 10 years old with a fever (≥ 37 °C) or history of fever within 24 h prior to the recruitment in the study. Whole blood samples were collected in vacutainers with EDTA for haemoglobin quantification, malaria diagnosis and molecular analysis. Malaria diagnosis conducted by examining Giemsa-stained thick and thin blood smears using a light microscopy.

Molecular analysis {#Sec4}
------------------

### DNA extraction and *Plasmodium falciparum* detection {#Sec5}

The QIAamp DNA blood Mini Kit (Qiagen, Hilden, Germany) was used to extract genomic DNA from archived EDTA blood following the manufacturer's instructions. DNA samples were stored at − 20 °C. The merozoite surface protein 1 gene (*Pfmsp1*) was used to genotype *P. falciparum* isolates as described elsewhere \[[@CR21]\]. This was performed to detect the presence of *P. falciparum* infection.

### *G6PD* genotyping {#Sec6}

A single-step PCR approach was used to amplify a 968 bp fragment of the G6PD gene (*G6PD*) as described by Nguetse et al. \[[@CR22]\]. Briefly, DNA was added into a reaction mixture (20 µl) containing 1× PCR buffer, 1× Q-reagent, 1.5 Mm MgCl~2~, 200 µM dNTPs, 100 Nm of each primer and 1U Taq DNA polymerase. The primers (forward primer 5′-GCCCCTGTGACCTCCCGCCA-3′ and reverse primer 5′-GCAACGGCAAGCCTTACATCTGG-3′) used here amplified a *G6PD* fragment containing the 202G\>A (rs1050828) and 376A\>G (rs1050829) single nucleotide polymorphisms. The thermal cycler conditions were 94 °C for 5 min followed by 30 cycles at 94 °C for 30 s, 67 °C for 1 min and 72 °C for 1 min and a final extension step at 72 °C for 5 min. The amplicons were separated by gel electrophoresis using a 1.2% agarose gel. The PCR products were purified using Sephadex™ G-50 fine DNA grade (GE Healthcare, Buckinghamshire, UK) and subsequently Sanger sequenced by the 3130 xl Genetic Analyzer (Applied Biosystems, CA, USA) in the forward and reverse direction using the foregoing primers and the BigDye Terminator v.1.1 cycle sequencing kit (Applied Biosystems, Foster City, USA). The BioEdit software (<http://www.mbio.ncsu.edu/BioEdit/bioedit.html>) was used to align the forward and reverse sequences using *G6PD* (NG_009015.2) as a reference, visually inspect the DNA sequence chromatograms to resolve discordant base calls and identify alleles G and/or A at position 202 and alleles A and/or G at position 376 of *G6PD*.

### Data analysis {#Sec7}

The Stata software was used to analyse the data. The Mann--Whitney and Kruskal--Wallis tests were applied to compare the mean ranks between G6PD groups. Chi square test was applied to compare proportions. Significance was observed at a *p*-*value *\< 0.05.

Results {#Sec8}
=======

A total of 229 febrile children were eligible for inclusion in this study. Of this, 212 participants were successfully genotyped for the G6PD deficiency. The remaining 4 and 13 participants were excluded from the study due to lack of adequate DNA (degradation of DNA during conservation or no sample available) samples for analyses and failure to obtain nucleotides sequences despite repeat attempts, respectively. The baseline characteristics of the participants are shown in Table [1](#Tab1){ref-type="table"}.Table 1Baseline characteristics of the participantsCharacteristicsValuesMean age in years ± SD (range)3.1± 2.5 (1--10)Sex ratio (M/F)1:1 (112/100)*Haemoglobin status*Normal (HbAA)187 (88.2%)Sickle cell anaemia (HbAS)25 (11.8%)Mean haemoglobin level (g/dl)11.4 ± 4.3Mean haematocrit (%)32.8 ± 13.1Mean red blood cell count (1 × 10^12^/L)5.1 ± 1.9Mean white blood cell count (1 × 10^9^/L)12.4 ± 6.7Mean platelet count (1 × 10^9^/L)277.2 ± 158.1Median parasitaemia (parasites/µl)10,101 (118.5--280,828)*Malaria diagnosis*Uncomplicated malaria22 (10.4%)Submicroscopic infection52 (24.5%)Malaria negative138 (65.1%)

Sanger sequencing was used to determine the G6PD genotype and infer the G6PD phenotype of the participants based on the allele (s) present at nucleotide positions 202G\>A (rs1050828) and 376A\>G (rs1050829), as described in "[Methods](#Sec2){ref-type="sec"}" section. Most of the participants (53%; 113/212) had the wild-type G6PD genotype (B hemizygous for males and BB homozygous for females) whereas 13% of the participants had G6PD deficient genotype (A− for males and A−A− for females) (Table [2](#Tab2){ref-type="table"}). The occurrence of G6PD deficient genotype was observed to be significantly higher among male participants (21%) than among the female participants (3%) (*p* \< 0.05). In contrast, the presence or absence of *P. falciparum* infection did not associate with G6PD genotype (*p* \> 0.05) of male and female febrile children (Table [3](#Tab3){ref-type="table"}). Similarly, the G6PD genotype of male and female Congolese children did not associate with six out of eight study population characteristics (Table [4](#Tab4){ref-type="table"}). The mean red blood and the mean platelet counts were, however, observed to be significantly lower in hemizygous male (G6PD A−) participants than in normal male (G6PD A+ or B) participants (*p* \< 0.05). No significant differences were found in the different female G6PD genotype groups.Table 2The frequency of G6PD genotypes among male and female Congolese childrenGenderGenotypeGenotype Frequency n (%)MaleB67 (59.8)A+21 (18.8)A−24 (21.4)FemaleBB46 (46)BA+22 (22)BA−11 (11)A+A+4 (4)A+A−14 (14)A−A−3 (3)Overall*A*− *and A*−*A*−*27 (13)*G6PD genotype: male normal = A+ or B; male hemizygous = A−; female normal = BB or BA+ or A+A+; female heterozygous = BA− or A+A−; female homozygous = A−A−; Hb = haemoglobin; Italic = severe G6PD deficiency genotypes Table 3Distribution of G6PD phenotype among Congolese children based on *Plasmodium falciparum* malaria diagnosis resultsGenderG6PD phenotypeMalaria negative, n (%)Uncomplicated malaria n (%)Sub-microscopic infection n (%)MaleG6PD normal57 (64.8)10 (11.4)21 (23.9)G6PD deficiency19 (79.2)1 (4.2)4 (16.7)FemaleG6PD normal43 (59.7)8 (11.1)21 (29.2)G6PD heterozygous18 (72.0)2 (8.0)5 (20.0)G6PD deficiency1 (33.3)1 (33.3)1 (33.4) Table 4Association between study population characteristics and G6PD phenotypes in male and female Congolese childrenMean age in years ± SD3.27 ± 2.512.50 ± 1.880.1062.97 ± 2.61)3.20 ± 2.553 ± 2.640.843Parasitaemia geometric mean4094 (191--151,010)1000--15,486 (158--280,827)520 (315--862)73,538--Mean haemoglobin level ±SD (g/dl)11.26 ± 1.8310.83 ± 0.940.11811.91 ± 7.0111.06 ± 1.3710.56 ± 1.250.547*Haemoglobin status*HbAA n (%)78 (88.6)23 (95.8)0.29663 (87.5)20 (80)3 (100)0.507HbAS n (%)10 (11.4)1 (4.2)9 (12.5)5 (20)0 (0)Mean haematocrit ± SD (%)32.48 ± 5.4430.79 ± 2.940.04734.36 ± 21.4331.54 ± 4.1729.76 ± 4.400.466Mean red blood cell count ± SD (10^12^/L0)5.13 ± 0.804.67 ± 0.500.0015.35 ± 3.244.8 ± 0.704. 62 ± 0.070.334Mean White blood cell count ± SD (10^9^/L)12.27 ± 5.413.29 ± 6.480.48512.9 ± 8.6311.85 ± 4.677.39 ± 2.190.247Mean platelet count ± SD (10^9^/L)283.27 (149.26)194.58 ± 141.130.01286.48 ± 166.07297.08 ± 146.71369.33 ± 311.180.896Parasite geometric mean given in parasites/µl

Discussion {#Sec9}
==========

This study investigated the prevalence of G6PD deficiency in febrile children from Brazzaville, Republic of Congo. This study shows that 13% of the children were carriers of the severe G6PD deficiency genotype (A− for males and A−A− for females). This finding is consistent with studies conducted in the other Central African countries where the prevalence of G6PD deficiency ranges from 9 to 22% \[[@CR22]--[@CR26]\]. Previous studies reported a higher G6PD deficiency prevalence (22%) in 1988 and 1998 among children with sickle cell anaemia in the current setting \[[@CR27], [@CR28]\]. Based on gender, higher G6PD deficiency prevalence was observed among male participants (21%) than female participants (3%). This is consistent with the higher susceptibility of males to G6PD deficiency than females owing to the X-linked inheritance *G6PD* deficient alleles (SNPs) and the hemizygous nature of the X-chromosome in males.

G6PD deficiency has a heterogeneous impact on the severity of malaria. Ruwenda et al. and Nguetse et al. showed that G6PD deficient males and heterozygous females were less susceptible to severe malaria \[[@CR10], [@CR22]\]. A similar phenomenon was observed in Cameroon with G6PD deficient participants having reduced parasitaemia, lower severity of anaemia and malaria symptoms and higher haemoglobin compared to the non-deficient individuals \[[@CR24]\]. Nevertheless, G6PD deficiency in Kenya and Tanzania was reported to protect only heterozygous females against severe malaria \[[@CR29], [@CR30]\], whereas in Mali it protected only hemizygous males against severe malaria \[[@CR31]\]. The absence of an association between G6PD deficiency and severe malaria has also been reported previously \[[@CR12], [@CR32]\].

A similar heterogeneity has also observed in the protection of G6PD deficiency against uncomplicated malaria. High incidence of uncomplicated malaria was observed in heterozygous females and hemizygous males with G6PD A− compared to participants with the wild-type genotype \[[@CR33]\]. Other studies have shown, on one hand, hemizygous males to be more susceptible to uncomplicated malaria whereas others have reported heterozygous females are more susceptible. For instance, Lwanira et al. reported a higher incidence of uncomplicated malaria in Ugandan G6PD deficient males (202G\>A) than those carrying the wild-type genotype \[[@CR34]\]. Another study from Gabon showed higher uncomplicated malaria incidence in heterozygous females \[[@CR23]\]. This finding has also been observed in Ghana as well as in Mali \[[@CR35], [@CR36]\]. Even though the study shows that uncomplicated malaria was less prevalent in G6PD deficient males and heterozygous females than in children with G6PD normal, the difference did not reach statistical significance (*p *\> 0.05).

Analysis of the association between haemoglobin (Hb) levels and G6PD deficiency in this study showed that mean Hb levels were similar in G6PD deficient children, G6PD heterozygous female children and G6PD normal children. This is congruent with findings from studies conducted in Angola, Ghana and Burkina Faso \[[@CR25], [@CR35]\]. Low Hb levels in G6PD deficient patients with sickle cell anaemia (HbSS) \[[@CR12], [@CR22]\] and the association of reduced erythrocyte lifespan with G6PD deficiency \[[@CR37], [@CR38]\] have also been observed previously.

G6PD deficiency is also an important factor to be considered prior to the administration of some drugs. This is because G6PD is a key enzyme involved in the production of the reduced form of nicotinamide adenine dinucleotide phosphate (NADPH) required by erythrocytes to withstand oxidative stress \[[@CR2]\]. Primaquine (PQ) is a classical example of oxidative drugs that induce acute haemolytic anaemia due to the suboptimal activity of G6PD which associated with the presence of *G6PD* SNP(s). PQ is highly efficacious against *P. falciparum* gametocytes \[[@CR16], [@CR17]\] and it is recommended, with combination current artemisinin-combined therapy, for the reduction *P. falciparum* transmission \[[@CR13], [@CR15]\]. Of this, PQ offers a viable strategy to reduce malaria transmission in the Republic of Congo where malaria is still a major health problem. However, high G6PD deficiency prevalence observed in the present study suggests that caution should be taken before the presumptive use of PQ in the Republic of Congo.

Conclusions {#Sec10}
===========

Taken together, this study provides an update on G6PD deficiency in children from Brazzaville, Republic of Congo. Understanding the distribution of G6PD deficiency in other geographical regions is recommended to inform the use of malaria intervention(s) such as primaquine that induces acute haemolytic anaemia in G6PD deficient individuals.
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